After several months of organizing and developing a location, the Global Stem Cells Group has finalized the construction of a laboratory and regenerative medicine research center in Uccle, Belgium.
This facility serves both as a regenerative medicine treatment and research center, but also as a plastic surgery clinic. In addition to this, one of the primary goals of the Center is to serve as a place for the fostering of knowledge and experience regarding the different products and equipment required for the application of cellular therapies. As part of the inaugural ceremony a group of physicians were trained in the setup and use of the various regenerative medicine protocols and application process of these cells into the patients.
This center is a push into Europe for the Global Stem Cells Group. As the science advances, newer and more advanced therapies and technologies are being developed and released into the market with each passing month.
With the European Union being one of the largest consumer markets in the world, the finalization of a brick-and-mortar location in Brussels, Belgium is one that will mean great things for the Global Stem Cells Group, and the presence and proliferation of regenerative medicine throughout Europe and the world.
“This was a wonderful opportunity that we could have. It goes to show that even during this pandemic, the medical community is one that is still going strong. We’re still rallying together to look for new breakthroughs, and come up with the most beneficial treatment options for patients,” Said Benito Novas, founder of the International Society for Stem Cell Applications, “In addition to this, it also provides an excellent platform for the distribution of regenerative medicine therapies and equipment, including the revolutionary new GCell Machine,”
Indeed, the inaugural training at the Stem Cell Center in Uccle, Belgium was one that covered both of the more traditional methods of stem cell isolation and application– adipose and bone-marrow derived autologous cells, but this training was also one of the first in which the company had the ability to demonstrate the novel GCell Machine. Using a precise system of blades and filters, it is able to process a stem cell sample from adipose tissue in less than half of the time that it would take a physician to do so through traditional means.
This allows the patient to be more comfortable throughout the shorter procedure, as less anesthesia is also required than when operating under traditional means. The GCell is a minimally invasive, portable machine that allows physicians to fully unlock the potential of regenerative medicine as a component in their practice. Using their global network of distributors and licensed vendors, Global Stem Cells Group is working fervently to ensure no interruption in the global availability of the most cutting-edge regenerative medicine products.
Stem Cells are revolutionizing the field of regenerative medicine, due to their intelligence. Once administered into the patient, they are able to identify and target areas of disease and damage. Adimarket’s Mesenchymal Stem Cell Product excretes growth factors, cytokines, and proteins, which all play a key role in the regeneration of tissue. Their anti-inflammatory and immunomodulatory properties mean that it is difficult for them to be rejected by the body. Additionally, they increase blood flow to the vital organs which need it the most.
Many proprietors of MSC products will claim that it is not necessarily important to have a high ratio of viable cells. They claim that it does not matter how many cells are ‘not viable’, or dead, so long as there is a high enough number of viable cells– however, current research has shown that this is not the case. These dead cells are detectable by the immune system, and it is believed that they can create an inflammatory response within the body at the treatment area, which would lower the effectiveness of the regenerative medicine treatments.
This bending of the science is harmful to our industry, which is why knowledgeable purveyors put one thing above all else– consistency. Our cellular concentrations are the same throughout each batch, and we make sure that there is a high ratio of viable cells. All of our samples are independently verified by a third party laboratory, and have been selected for their phenotypic and genotypic profile, characterized for optimum growth and stability. When the proper care is taken, Mesenchymal Stem Cell products have been identified as having the highest output of growth factors and stem cell factors among the current standards of care– as well as properties of angiogenesis, immunomodulation, and the potential for endogenous repair.
Cellgenic has been working for over a decade, constantly reinventing itself and reinforcing the products that we offer with the latest advancements in the field of regenerative medicine. We take every painstaking measure possible to ensure that the cellular samples that our customers use to treat their patients are second to none– this includes the consistent concentrations of our sample, which are the same throughout ensuring that every patient gets the same treatment. We offer the product in 10 million or 30 million live total nucleated cells, where other fabricators would have the same number of total cells. We ensure that every single product that we send out has been tested for low amounts of annexin, which is a cellular protein which serves as a marker for cell death.
All our Mesenchymal Stem Cell products come in 1cc vials cryogenically preserved– they are shipped overnight within the United States, conveniently delivered to your door in the morning. For use, the product is passively thawed between the palms of your hands– and ready to use when your patients are. MSC 10 contains 10 million live cells and is recommended for a single joint, or a small area. However, the MSC pure pro has 30 million live cells,and can be used for larger applications, or for up to three joints in the same patient at the same time.
If you are interested in finding out more about Cellgenic MSCs, you can send an eMail to email@example.com
The Global Stem Cells Group, a multi-disciplinary community of scientists and physicians that are collaborating to treat diseases and lessen human suffering through the advancement of the field of regenerative medicine has announced plans for a training in Brussels, Belgium on April 9/10th. This course is a long-awaited return to the country of Belgium after months of inactivity in the region brought about by the COVID-19 pandemic. During this time, research proceeded, and shocking discoveries were made that further thrust regenerative medicine into the world’s stage, and as a result the curriculum has been reinforced with the latest in IV therapy and exosome protocols.
This training will be one of the first of 2021, reaffirming the Global Stem Cells Group’s presence in Europe as a key player in the field of regenerative medicine. Members from both Global Stem Cells Group & the International Society for Stem Cell Application’s Brussels Chapter will be there to assist in expanding research for and the practice of regenerative medicine across Europe.
“It’s good to know that the Global pandemic has not been able to stop the progress of business,” Says Benito Novas, founder and CEO of the Global Stem Cells Group, “With reopening happening slowly, but surely, we hope that more and more physicians and clinics will take up the benefits of regenerative medicine.As we continue to train patients with the GCell Machine, ”
This training is intended to teach physicians the value and process behind incorporating regenerative medicine into their own clinical practice. This includes a theoretical portion that goes over basic regenerative medicine biology and its application, but also includes a Hands-On portion in which doctors, in a controlled environment and guided by a team of medical professionals, will have the opportunity to see procedures be performed just a few feet away, and then get the opportunity to try it for themselves.
The Belgium Stem Cell Center is one that is outfitted with the latest technology in regenerative medicine processing, which ensures any students that pass through it receive an education in extraction, isolation, and application of Platelet-Rich Plasma, Adipose, and Bone Marrow-Derived Mesenchymal Stem Cells.
This training will also teach physicians how to utilize the GCell Machine to perform regenerative medicine therapies. GCell is a tissue homogenization device that is revolutionizing the future of regenerative medicine. It is an extremely compact, all-in-one unit that can homogenize and isolate the stem cells from an adipose sample. GCell’s process of homogenizing with a system of precise blades and filtering ensures that the sample can be processed within an hour, with little input from the physician when the machine begins to do its work.
Once the process is over, the end result is a final product that can be administered to patients within an hour after the initial tissue extraction. This is a far cry from the previous, muti-hour long treatments that physicians have grown accustomed to, and the shortened timespan and simplicity of the procedure is something that both doctors and their patients will greatly appreciate.
If you are interested in enrolling in this upcoming event, or to learn more about the different training opportunities available, you can visit us at our training website.
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/